Carregant...
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relaps...
Guardat en:
| Publicat a: | Ther Adv Hematol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970705/ https://ncbi.nlm.nih.gov/pubmed/33796237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620721989588 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|